Search

Your search keyword '"Advani, Anjali S."' showing total 1,162 results

Search Constraints

Start Over You searched for: Author "Advani, Anjali S." Remove constraint Author: "Advani, Anjali S."
1,162 results on '"Advani, Anjali S."'

Search Results

1. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

2. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia.

3. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL

4. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

5. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

8. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

9. Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

10. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

12. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.

15. Mutation profiles and outcomes of patients with acute myeloid leukemia with autoimmune disease.

16. A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia.

17. Outcomes of blast-phase MPN and JAK2, MPL, and CALRmutated de novo AML: A propensity score-adjusted cohort study.

18. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

20. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

21. A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit–positive Acute Myeloid Leukemia

22. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

23. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

25. Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL

26. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)

27. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy

28. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

29. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

30. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

31. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

33. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

39. POSTER: MDS 684 Clonal Hematopoiesis of Indeterminate Potential (CHIP) Clinic: The Cleveland Clinic Experience

40. MDS-684 Clonal Hematopoiesis of Indeterminate Potential (CHIP) Clinic: The Cleveland Clinic Experience

41. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

44. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia

46. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

47. Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes

48. Supplemental Figure 1 from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

49. Supplementary Data from Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Catalog

Books, media, physical & digital resources